Regional variations in human papillomavirus prevalence across time in NHANES (2003–2014)

Research output: Contribution to journalArticle

Abstract

Introduction: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time. Methods: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003–2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007–2014) to assess their effects on observed associations. Results: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003–2006) and early post-licensure cycles (2007–2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011–2014) compared to prevaccine years (2003–2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination. Conclusions: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.

Original languageEnglish (US)
JournalVaccine
DOIs
StatePublished - Jan 1 2019

Fingerprint

National Health and Nutrition Examination Survey
Papillomaviridae
Nutrition Surveys
Papillomavirus Vaccines
Licensure
Vaccination
vaccination
vaccines
Human papillomavirus 11
Human papillomavirus 6
DNA Fingerprinting
Censuses
Uterine Cervical Neoplasms
Vaccines
Logistic Models
uterine cervical neoplasms
DNA fingerprinting
Incidence

Keywords

  • Cancer prevention
  • Geographic disparities
  • HPV prevalence
  • HPV vaccination
  • Vaginal HPV

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{2fb19f09a959454cac68004153b121e3,
title = "Regional variations in human papillomavirus prevalence across time in NHANES (2003–2014)",
abstract = "Introduction: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time. Methods: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003–2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007–2014) to assess their effects on observed associations. Results: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003–2006) and early post-licensure cycles (2007–2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011–2014) compared to prevaccine years (2003–2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6{\%}) and Midwest (8.6{\%}), followed by the West (4.8{\%}), and the Northeast (3.5{\%}) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination. Conclusions: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.",
keywords = "Cancer prevention, Geographic disparities, HPV prevalence, HPV vaccination, Vaginal HPV",
author = "Jacqueline Hirth and Kuo, {Yong Fang} and Jonathan Starkey and Richard Rupp and Laz, {Tabassum H.} and Mahbubur Rahman and Abbey Berenson",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2019.06.001",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Regional variations in human papillomavirus prevalence across time in NHANES (2003–2014)

AU - Hirth, Jacqueline

AU - Kuo, Yong Fang

AU - Starkey, Jonathan

AU - Rupp, Richard

AU - Laz, Tabassum H.

AU - Rahman, Mahbubur

AU - Berenson, Abbey

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time. Methods: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003–2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007–2014) to assess their effects on observed associations. Results: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003–2006) and early post-licensure cycles (2007–2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011–2014) compared to prevaccine years (2003–2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination. Conclusions: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.

AB - Introduction: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time. Methods: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003–2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007–2014) to assess their effects on observed associations. Results: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003–2006) and early post-licensure cycles (2007–2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011–2014) compared to prevaccine years (2003–2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination. Conclusions: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.

KW - Cancer prevention

KW - Geographic disparities

KW - HPV prevalence

KW - HPV vaccination

KW - Vaginal HPV

UR - http://www.scopus.com/inward/record.url?scp=85066866337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066866337&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.06.001

DO - 10.1016/j.vaccine.2019.06.001

M3 - Article

C2 - 31182324

AN - SCOPUS:85066866337

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -